368 related articles for article (PubMed ID: 30718087)
1. Moderately Hypofractionated Radiotherapy in Node-positive Prostate Cancer.
Mallick I; Das A; Arunsingh M
Clin Oncol (R Coll Radiol); 2019 Apr; 31(4):260-264. PubMed ID: 30718087
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
4. Moderately Hypofractionated Radiotherapy and Androgen Deprivation Therapy for High-risk Localised Prostate Cancer: Predictors of Long-term Biochemical Control and Toxicity.
Maulik S; Arunsingh M; Arun B; Prasath S; Mallick I
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e52-e60. PubMed ID: 34456107
[TBL] [Abstract][Full Text] [Related]
5. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience.
Hegazy MW; Mahmood RI; Al Otaibi MF; Khalil EM
J Egypt Natl Canc Inst; 2016 Jun; 28(2):101-10. PubMed ID: 27133975
[TBL] [Abstract][Full Text] [Related]
7. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
9. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.
Teh BS; Lewis GD; Mai W; Pino R; Ishiyama H; Butler EB
Cancer Commun (Lond); 2018 Apr; 38(1):11. PubMed ID: 29764515
[TBL] [Abstract][Full Text] [Related]
11. Early Results of Extreme Hypofractionation Using Stereotactic Body Radiation Therapy for High-risk, Very High-risk and Node-positive Prostate Cancer.
Murthy V; Gupta M; Mulye G; Maulik S; Munshi M; Krishnatry R; Phurailatpam R; Mhatre R; Prakash G; Bakshi G
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):442-447. PubMed ID: 29571936
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
[TBL] [Abstract][Full Text] [Related]
13. Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial.
Glicksman RM; Loblaw A; Morton G; Szumacher E; Chung HT; Vesprini D; Chu W; Liu SK; Choo R; Deabreu A; Mamedov A; Zhang L; Cheung P
Radiother Oncol; 2021 Oct; 163():21-31. PubMed ID: 34324914
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial.
Magli A; Moretti E; Tullio A; Giannarini G; Tonetto F; Urpis M; Crespi M; Foti C; Prisco A; Polsinelli M; De Giorgi G; Bravo G; Scalchi P; Trovò M
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):269-276. PubMed ID: 29520019
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of moderately hypofractionated radiotherapy (67.5 Gy in 25 fractions) for prostate cancer confined to the pelvis: a single center retrospective analysis.
Yao L; Shou J; Wang S; Song Y; Fang H; Lu N; Tang Y; Chen B; Qi S; Yang Y; Jing H; Jin J; Yu Z; Li Y; Liu Y
Radiat Oncol; 2020 Oct; 15(1):231. PubMed ID: 33008404
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer.
Nakamura K; Ikeda I; Inokuchi H; Takayama K; Inoue T; Kamba T; Ogawa O; Hiraoka M; Mizowaki T
J Radiat Res; 2018 Sep; 59(5):656-663. PubMed ID: 30085048
[TBL] [Abstract][Full Text] [Related]
17. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
18. Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis.
Tamihardja J; Schortmann M; Lawrenz I; Weick S; Bratengeier K; Flentje M; Guckenberger M; Polat B
Strahlenther Onkol; 2021 Feb; 197(2):124-132. PubMed ID: 32833036
[TBL] [Abstract][Full Text] [Related]
19. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
[TBL] [Abstract][Full Text] [Related]
20. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
